About Prolacta Bioscience

Prolacta Bioscience is a privately-held life sciences company dedicated to Advancing the Science of Human Milk®. The company pioneered the development of human milk-based Neonatal Nutritional Products to meet the needs of critically ill, premature infants in the NICU. Prolacta leads the industry in the quality and safety of nutritional products made from breast milk and operates the first and only pharmaceutical-grade manufacturing facility for the processing of human breast milk.

NOTE: Product used in these studies was named Prolact+ H2MF®. The formulation of Prolact+ H2MF® and HumavantTM HMF is the same. Prolact+ H2MF® is the trade name in North America, and HumavantTM HMF is the trade name outside North America. The products shown are distributed in the United Kingdom and Ireland.

  1. Abrams SA, Schanler RJ, Lee ML, Rechtman DJ. Greater mortality and morbidity in extremely preterm infants fed a diet containing cow milk protein products. Breastfeed Med. 2014;9(6):281-285.
  2. Hair AB, Peluso AM, Hawthorne KM, et al. Beyond necrotizing enterocolitis prevention: improving outcomes with an exclusive human milk–based diet. Breastfeed Med. 2016;11(2):70-74.

Important notice: The Humavant™ product family, except for Humavant™ HM, is considered food for special medical purposes for the dietary management of preterm infants (in Germany, Humavant™ HM is also a food for special medical purposes; it is classified as food in all other European countries). Humavant™ products are not suitable as the sole source of nutrition. Infants may require additional vitamins and iron added separately from the product. Humavant™ products should only be used under medical supervision and are not suitable for parenteral use.